Literature DB >> 29373243

Haploidentical stem cell transplantation in a boy with chronic granulomatous disease.

A Regueiro-García1, S Fariña-Nogueira2, J Á Porto-Arceo3, J M Couselo-Sánchez2.   

Abstract

Chronic granulomatous disease is a primary immunodeficiency caused by mutations in any one of the five components of the NADPH oxidase in phagocytic leucocytes. This causes impaired microbial killing, which leads to severe life-threatening bacterial and fungal infections. Currently, allogenic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for chronic granulomatous disease, although gene therapy may provide a new therapeutic option for the treatment of patients with CGD. Haploidentical HSCT provides a potentially curative treatment option for patients who lack a suitably HLA-matched donor, but only a few cases have been reported in the literature. Herein, we report a boy with X-linked chronic granulomatous disease treated successfully by haploidentical HSCT with post-transplant cyclophosphamide using a treosulfan-based conditioning regimen.
Copyright © 2017 SEICAP. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Chronic granulomatous disease; Haploidentical; Hematopoietic stem cell transplantation; Immunologic deficiency syndromes; Treosulfan

Mesh:

Substances:

Year:  2018        PMID: 29373243     DOI: 10.1016/j.aller.2017.09.020

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  1 in total

1.  Failure to Prevent Severe Graft-Versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Chronic Granulomatous Disease.

Authors:  Mark Parta; Dianne Hilligoss; Corin Kelly; Nana Kwatemaa; Narda Theobald; Christa S Zerbe; Steven M Holland; Harry L Malech; Elizabeth M Kang
Journal:  J Clin Immunol       Date:  2020-04-20       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.